Avadel Pharmaceuticals PLC
$9.20
(as of Jun 20, 3:59 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Avadel Pharmaceuticals PLC
Stock Price
$9.20
Ticker Symbol
AVDL
Exchange
NASDAQ
Industry Information for Avadel Pharmaceuticals PLC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Company Description for Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Fundamentals for Avadel Pharmaceuticals PLC
Market Capitalization
$901,606,464
EBITDA
$-16,400,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
22.47
Earnings per Share
$-0.26
Earnings per Share Estimate Next Year
Profit Margin
-13.58%
Shares Outstanding
96,738,896
Percent Owned by Insiders
4.92%
Percent Owned by Institutions
83.29%
52-Week High
52-Week Low
Technical Indicators for Avadel Pharmaceuticals PLC
Analyst Ratings for Avadel Pharmaceuticals PLC
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
0
News About Avadel Pharmaceuticals PLC
Jun 16, 2025, 4:05 PM EST
DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two new employees to purchase 9,600 ordinary shares under Avadel’s 2021 Inducement Plan. See more.
Jun 13, 2025, 12:20 PM EST
Avadel (AVDL) could be a solid choice for investors given the company's remarkably improving earnings outlook. See more.
Jun 5, 2025, 10:53 AM EST
[asian woman sleepless at night]
See more.
Jun 5, 2025, 7:30 AM EST
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. See more.